title: Monoclonal antibody-based therapy for neuroblastoma.
abstract: Dose-intensive combination chemotherapy can improve the clinical response of many pediatric solid tumors. However, cure remains elusive. Stage 4 neuroblastoma stands out as an exception. Part of this success is a result of antibody-based strategies, which include immunomagnetic purging of autologous marrow prior to autologous marrow transplantation and immunotherapy directed at minimal residual disease. It is striking that treatment with monoclonal antibodies, even when targeted at a single antigen, namely, ganglioside G(D2), can affect long-term progression-free survival among these patients. The potential role of the idiotype network in tumor control can be exploited clinically. The genetic engineering of these antibodies into novel forms holds great promise for more specific and effective targeting possibilities, including the delivery of cytokines and cells. Preclinical results are also promising. It is expected that the availability of novel antibodies directed at a broader spectrum of pediatric solid tumors will facilitate the successful application of this approach to more patients. Experience with metastatic neuroblastoma has provided proof of this principle. It is likely that other tumors will fall.
authors: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. cheungn@mskcc.org
authors: N K
authors: NK
authors: Cheung
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002648:Child; D016207:Cytokines / Q000627:therapeutic use; D018572:Disease-Free Survival; D005818:Genetic Engineering; D006801:Humans; D018189:Immunomagnetic Separation; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000276:immunology* / Q000628:therapy*; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines